Special Drug Use-results Surveillance of Scemblix Tablets
NCT05421091 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 550
Last updated 2024-03-27
Summary
Uncontrolled, central registration system, all-case, multicenter, special drug use-results surveillance.
Conditions
- Chronic Myeloid Leukemia
Interventions
- OTHER
-
Asciminib
Prospective observational study. There is no treatment allocation. Patients prescribed with asciminib are eligible to enroll into this study.
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Eligibility
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-07-04
- Primary Completion
- 2024-02-29
- Completion
- 2024-02-29
Countries
- Japan
Study Locations
More Related Trials
-
Asciminib Roll-over Study
NCT04877522 ·Status: RECRUITING ·Phase: PHASE4
-
Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database
NCT06148493 ·Status: COMPLETED
-
Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia
NCT05384587 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy
NCT01051063 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
NCT06629584 ·Status: RECRUITING ·Phase: PHASE2
-
Frontline Asciminib Combination in Chronic Phase CML
NCT03906292 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T315I Mutation - a Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)
NCT06211153 ·Status: COMPLETED
-
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
NCT00923182 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
NCT03578367 ·Status: COMPLETED ·Phase: PHASE2
-
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438 ·Status: RECRUITING ·Phase: PHASE3
-
RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)
NCT06684964 ·Status: RECRUITING
-
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
NCT06514534 ·Status: RECRUITING ·Phase: PHASE2
-
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
NCT04948333 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia
NCT06368414 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors
NCT04795427 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
NCT05326516 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia
NCT00510939 ·Status: UNKNOWN ·Phase: PHASE2
-
Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
NCT04666259 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
NCT06651229 ·Status: RECRUITING ·Phase: PHASE1
-
Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
NCT04402138 ·Status: COMPLETED ·Phase: PHASE2
-
Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma
NCT00532389 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia
NCT05963074 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
NCT05453903 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase
NCT05143840 ·Status: RECRUITING ·Phase: PHASE2